Neil Thompson appointed CSO of Healx Healx, a Cambridge, UK, technology company developing treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific Officer (CSO). more ➔
Harpreet Singh becomes CEO of Immatics Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has … more ➔
Jens-Peter Marschner joins Zelluna Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, announced the appointment of Jens-Peter Marschner as chief medical officer (CMO) at the end of June. more ➔
Helena Strigård becomes CEO of Swedenbio Swedenbio’s Board has appointed Helena Strigård as the new CEO. Strigård will take up the position on September 1 and replace Jonas Ekstrand, more ➔
Teckro Expands Leadership Team Teckro today announced five significant appointments to its leadership team. The hires follow Teckros Series C funding announcement in February, featuring investment from major US venture capital … more ➔
New CEO at Morphosys Germany-based MorphoSys AG announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer. The appointment will take effect on September 1, 2019. more ➔
New CEO for Valo Therapeutics Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already … more ➔
Lytix Biopharma brings two scientists on b...Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma from the MD Anderson Cancer Center to join the company as Company Strategic Advisors more ➔
ReViral Appoints Alex C. Sapir as CEO ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), today announced that Alex C. Sapir has been … more ➔
Paul Hudson to become Sanofi CEO At its meeting on June 6th of 2019, Sanofi’s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to ret … more ➔
